|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
17,843 |
$2,166,497.06 |
7.50% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
8,893 |
$2,120,624.78 |
7.34% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
35,422 |
$2,076,437.64 |
7.19% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
9,520 |
$1,979,588.80 |
6.85% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,100 |
$1,972,887.00 |
6.83% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
39,951 |
$1,075,480.92 |
3.72% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,413 |
$1,058,153.31 |
3.66% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
4,819 |
$1,038,590.88 |
3.59% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
7,416 |
$1,030,749.84 |
3.57% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
2,846 |
$999,002.92 |
3.46% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
5,759 |
$996,134.23 |
3.45% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
73,989 |
$996,631.83 |
3.45% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
8,426 |
$993,088.36 |
3.44% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,223 |
$969,828.21 |
3.36% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,630 |
$931,919.90 |
3.22% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
6,843 |
$657,407.01 |
2.27% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,347 |
$649,987.40 |
2.25% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
10,279 |
$455,051.33 |
1.57% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
3,657 |
$442,241.01 |
1.53% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
865 |
$426,903.45 |
1.48% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
5,449 |
$374,291.81 |
1.30% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,127 |
$373,607.55 |
1.29% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
6,318 |
$344,520.54 |
1.19% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,005 |
$339,439.10 |
1.17% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
2,630 |
$338,980.70 |
1.17% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
8,380 |
$279,556.80 |
0.97% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
10,925 |
$252,695.25 |
0.87% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
3,533 |
$181,207.57 |
0.63% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
2,611 |
$170,080.54 |
0.59% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,049 |
$170,302.77 |
0.59% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
7,459 |
$166,634.06 |
0.58% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
6,583 |
$164,180.02 |
0.57% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
12,984 |
$162,819.36 |
0.56% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,650 |
$163,053.00 |
0.56% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
766 |
$156,968.72 |
0.54% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,646 |
$156,699.20 |
0.54% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,238 |
$155,132.58 |
0.54% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
6,591 |
$153,372.57 |
0.53% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
456 |
$146,882.16 |
0.51% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
5,250 |
$148,102.50 |
0.51% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,012 |
$145,990.72 |
0.51% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
5,100 |
$147,696.00 |
0.51% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
2,836 |
$144,522.56 |
0.50% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
1,872 |
$140,718.24 |
0.49% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
551 |
$142,709.00 |
0.49% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,663 |
$141,438.15 |
0.49% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
2,776 |
$140,687.68 |
0.49% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
6,186 |
$134,483.64 |
0.47% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
5,633 |
$136,374.93 |
0.47% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,618 |
$127,174.80 |
0.44% |
| US Dollar |
$USD |
|
Other |
59,959 |
$59,958.84 |
0.21% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|